This is Vol.74 Newsletter for April 2026.
April 2026 highlighted how biopharma and healthcare are being reshaped at the same time by market pressure, regulatory shifts, and accelerating technology change. From the rise of China in global licensing and the evolution of oncology R&D, to U.S. tariff pressure, record K-bio exports, and supply-chain instability, the environment is becoming more complex and more strategic. In this landscape, success will depend not only on responding quickly, but on connecting regulatory insight, market timing, and execution with greater precision.
